CRISPR screening in hematology research: from bulk to single-cell level

Journal of Hematology & Oncology

Review

Jan Cools¹  Sofie Demeyer¹  Sarah Meyers¹ 

[1] Center for Human Genetics, KU Leuven, Leuven, Belgium;Center for Cancer Biology, VIB, Leuven, Belgium;Leuvens Kanker Instituut (LKI), KU Leuven – UZ Leuven, Leuven, Belgium;

关键词: Leukemia;    Hematology;    CRISPR/Cas9;    CRISPR screening;    Single-cell;    Perturb-seq;    CROP-seq;   

DOI  :  10.1186/s13045-023-01495-5

 received in 2023-07-13, accepted in 2023-08-21,  发布年份 2023

来源: Springer

【 摘 要 】

The CRISPR genome editing technology has revolutionized the way gene function is studied. Genome editing can be achieved in single genes or for thousands of genes simultaneously in sensitive genetic screens. While conventional genetic screens are limited to bulk measurements of cell behavior, recent developments in single-cell technologies make it possible to combine CRISPR screening with single-cell profiling. In this way, cell behavior and gene expression can be monitored simultaneously, with the additional possibility of including data on chromatin accessibility and protein levels. Moreover, the availability of various Cas proteins leading to inactivation, activation, or other effects on gene function further broadens the scope of such screens. The integration of single-cell multi-omics approaches with CRISPR screening open the path to high-content information on the impact of genetic perturbations at single-cell resolution. Current limitations in cell throughput and data density need to be taken into consideration, but new technologies are rapidly evolving and are likely to easily overcome these limitations. In this review, we discuss the use of bulk CRISPR screening in hematology research, as well as the emergence of single-cell CRISPR screening and its added value to the field.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 4

Fig. 3

Fig. 4

Fig. 1